Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugate includes potentiator; or composition comprising...
Patent
1995-06-06
1999-11-02
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugate includes potentiator; or composition comprising...
4241781, 5303873, 5303888, 5303917, A61K 4505
Patent
active
059765356
ABSTRACT:
Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.
REFERENCES:
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4867962 (1989-09-01), Abrams
patent: 4867973 (1989-09-01), Goers et al.
patent: 5225353 (1993-07-01), Berenson et al.
patent: 5256395 (1993-10-01), Barbet et al.
Konrad et al., "The Immune System as a Barrier to Delivery of Protein Therapeutics", in Biological Barriers to Protein Delivery, K.L. Audus and T.I. Raub Eds., Plenum Press, NY, 1993.
Spooner et al., Tibtech, 1990, 8:189.
Foon et al., Cancer Res., 1989, 49:1621.
Hoogenboom et al., Mol. Immunol., 1991, 28(9):1027-37.
Sheldon et al., "Targeting of [111In]Biocytin to Cultured Ovarian Adenocarcinoma Cells Using Covalent Monoclonal Antibody-Streptavidin Conjugates," Appl. Radiat. Isot., vol. 43, No.11, pp. 1399-1402, 1992.
Sharon and Lis, "Carbohydrates in Cell Recognition," Scientific American, vol. 268, No. 1, pp. 82-89, 1993.
Goodwin, "New Methods for Localizing Infection: A role for Avidin-Biotin?," vol. 33, No. 10, pp. 1816-1818, 1992.
Goodwin et al., "Pretargeted Immunoscintigraphy: Effect of Hapten Valency on Murine Tumor Uptake," J. Nucl. Med., vol. 33, No. 11, pp. 2006-2013, 1992.
Koch and Macke, "99m-Tc Labeled Biotin Conjugate in a Tumor "Pretargeting" Approach with Monoclonal Antibodies," Angew. Chem. Intl.Ed. Engl., vol. 31, No. 11, pp. 1507-1509, 1992.
Goodwin et al., Abstract No. 232, "Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-Biotin Immunoscintigraphy," J.Nucl. Med. p. 880, 1992.
Amato, "Hope for a Magic Bullet that Moves at the Speed of Light," Science, vol. 262, pp. 32-33, Oct. 1, 1993.
Rakestraw et al., "Antibody-targeted photolysis: In Vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using modified dextran carrier," Proc. Natl. Acad. Sci., vol. 87, pp. 4217-4221, 1990.
Devanathan et al., "Readily available flourescein isothiocyanate-conjugated antibodies can be easily converted into targeted phototoxic agents for antibacterial, antiviral, and anticancer therapy," Proc. Natl. Acad. Sci., vol. 87, pp. 2980-2984, 1990.
Kreimer-Birnbaum, "Modified Porphyrins, Chlorins, Phthalocyanines, and Purpurins: Second Generation Photosensitizers for Photodynamic Therapy," Seminars in Hematology, vol. 26, No. 2 (Apr.), pp. 157-173, 1989.
Pass, "Photodynamic Therapy Oncology: Mechanisms and Clinical Use," J. of the Natl. Cancer Institute, vol. 85, No. 6, pp. 443-456, 1993.
Herman et al., "Synthesis of Dextran Derivatives with Thiol-Specific Reactive Groups for the Preparation of Dextran-Protein Conjugates," Bioconjugate Biochem., vol. 4, pp. 402-405, 1993.
Goff et al., "Photoimmunotherapy of Human Ovarian Carcinoma Cells Ex Vivo," Cancer Research, vol. 51, pp. 4762-4767, 1991.
Burrows and Thorpe, "Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature, " Proc. Natl. Acad. Sci., vol. 90, pp. 8996-9000, 1993.
Bignami et al., "N-(4'-Hydroxyphenylacetyl)palytoxin: A Palytoxin Prodrug That can be Activated by a Monoclonal Antibody-Pencillin G Amidase Conjugate," Cancer Research, vol. 52, pp. 5759-5764, 1992.
International Search Report for PCT Patent Application No.: PCT/US93/05406.
Green, Biochem. J., 89:585, 1963, "The Use of [.sup.14 C]Biotin for Kinetic Studies and for Assay."
Kalofonos et al., J. Nucl. Med., vol. 31, No. 11, pp. 1791-1796, 1990, "Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication."
Hnatowich et al., J. Nucl. Med., vol. 28, No. 8, pp. 1294-1302, 1987, "Investigations of Avidin and Biotin for Imaging Applications."
Paganelli et al., Int. J. Cancer, 45:1184-1189, 1990, "Intraperitoneal Radio-Localization of Tumors Pre-Targeted by Biotinylated Monoclonal Antibodies."
Paganelli et al., Nuclear Medicine Communications, 12:211-234, 1991, "Monoclonal antibody pretargeting techniques for tumour localization: the avidin-biotin system."
Goodwin/Hnatowich, J. Nucl. Med., vol. 32, No. 4, pp. 750-751, 1991, Letter to the Editor/Reply.
Jain, Scientific American, 271:58, 1994.
Curti, Crit. Rev. Oncol./Hematol., 14:29, 1993.
The Merck Index, p. 174, Compound 1226, 1983.
Rosebrough, J. Nucl. Med., p. 880, 1992, Abstract No. 235, "Plasma Stability and Pharmacokinetics of Radio-Labeled Deferoxamine-Biotin Derivatives."
Virzi et al., J. Nucl. Med., p. 920, 1992, Abstract No. 403, "The Preparation and Evaluation of 12 Biotin Derivatives Labeled with Tc-99M."
Rosario et al., J. Nucl. Med., vol. 32, No. 5, p. 993, 1991, Abstract No. 356, "Bolton-Hunter and Biotin Derivatized Polylysine: A New Multi-Valent Peptide Reagent for In Vivo Pre-Targeting with Streptavidin Conjugates."
Abrams Paul G.
Axworthy Donald B.
Fritzberg Alan R.
Graves Scott S.
Kasina Sudhakar
Cunningham Thomas M.
NeoRx Corporation
LandOfFree
Pretargeting protocols for the enhanced localization of cytotoxi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pretargeting protocols for the enhanced localization of cytotoxi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pretargeting protocols for the enhanced localization of cytotoxi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2131457